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Abstract
Background No data on the long-term ‘real-world’ use of
fluvoxamine for the treatment of social anxiety disorder
(SAD) in Japanese patients are currently available.
Objective To evaluate the long-term safety and efficacy
of fluvoxamine for SAD in the clinical setting.
Methods Japanese patients with SAD who initiated treat-
ment with fluvoxamine were enrolled in this 53-week post-
marketing survey from 407 institutions nationwide. Data
including rates of adverse drug reactions (ADRs) and effi-
cacy were collected. Overall improvement was assessed
using the Clinical Global Impression for Improvement. SAD
symptoms and treatment responses were assessed with the
Japanese version of the Liebowitz Social Anxiety Scale.
Results From the 1,974 patients surveyed, 1,790 and 1,504
patients were eligible for analysis of safety and efficacy,
respectively. ADRs were reported in 18.2 % of patients, with
nausea, somnolence, and constipation the most common. Over
50 % of these ADRs developed in the first 4 weeks of treat-
ment. Serious ADRs were reported in 0.8 % of patients and
included six cases of suicide attempt and three cases of suicidal
ideation. Response to fluvoxamine was reported in 78.4 % of
patients. In patients comorbid with depression, improvement
in SAD symptoms with fluvoxamine treatment was signifi-
cantly affected by clinical improvement in the depression.
Conclusions These findings support the long-term safety
and efficacy of fluvoxamine in patients with SAD. Most
ADRs developed during the early treatment phase, and
higher doses during the later phase were not associated
with an increase in ADRs.
Key Points
Since the approval of fluvoxamine in Japan, no data
on the long-term ‘real-world’ use of fluvoxamine for
the treatment of social anxiety disorder in Japanese
patients have been available.
To address this, a post-marketing survey of the long-term
administration of fluvoxamine in patients with social
anxiety disorder in the clinical setting was initiated.
This survey demonstrated that fluvoxamine is safe
and efficacious for the long-term treatment of
Japanese patients with social anxiety disorder in a
clinical setting.
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Introduction
Fluvoxamine maleate (hereinafter referred to as fluvox-
amine) was approved in April 1999 as Japan’s first selec-
tive serotonin reuptake inhibitor (SSRI) on the basis of
efficacy and safety data in patients with depression/
depressive state [1–3] and obsessive-compulsive disorder
(OCD) [4, 5]. It became commercially available in May
1999 as a drug indicated for the treatment of these
indications.
The efficacy and tolerability of fluvoxamine have also
been investigated in a 10-week placebo-controlled, dou-
ble-blind study in 265 Japanese patients with social
anxiety disorder (SAD) followed by a 52-week open-
label extension study [6]. However, such clinical trials
with antidepressants were designed to include highly
homogeneous samples in order to decrease heterogeneity
in treatment response [7–13]. As a result, it has been
pointed out that more than 70 % of typical patients with
SAD would be excluded from participation in clinical
trials on pharmacological efficacy for SAD by exclusion
criteria [14]. Therefore, examination of treatment out-
comes in a broader range of target population suffering
from the disorder is required to establish better
pharmacotherapy.
In this study, fluvoxamine significantly reduced the
total score of the Japanese version of the Liebowitz Social
Anxiety Scale (LSAS-J) compared with placebo [6]. On
the basis of the positive results of this study and its open-
label extension, the Japanese Ministry of Health, Labor
and Welfare (MHLW) approved fluvoxamine as the first
drug in Japan indicated for the treatment of SAD in
October 2005. However, since the approval of fluvox-
amine in Japan no data on the long-term ‘real-world’ use
of fluvoxamine for the treatment of SAD in Japanese
patients have been collected. To address this, a special
post-marketing survey of the long-term administration of




Patients who visited the medical institutions participating
in the survey, were diagnosed with SAD based on the
Diagnostic and Statistical Manual of Mental Disorders,
Fourth Edition, Text Revision (DSM-IV-TR) diagnostic
criteria, and were initiating fluvoxamine for an expected
treatment duration of at least 53 weeks were eligible for
enrollment.
Study Design
This survey was conducted according to the MHLW
Ordinance on Good Post-Marketing Study Practice
(MHLW Ordinance Related to Standards for Conducting
Post-Marketing Surveys and Studies on Drugs; Ministerial
Ordinance No. 171 issued by the MHLW on 20 December
2004). Eligible patients were registered within 14 days
after starting fluvoxamine using a central registration sys-
tem, and patient data were recorded from baseline to the
end of the observation period using case report forms
(CRFs). The study was conducted between January 2006
and December 2008 with patient registration open between
April 2006 and December 2007. Patients were planned to
be followed for 53 weeks, but patients who discontinued or
completed fluvoxamine treatment before week 53 were
followed up from baseline to the end of their treatment.
Study Outcomes
The following data were recorded for each patient: (1)
patient characteristics; (2) history of SAD treatment; (3)
dosage regimen of fluvoxamine treatment, concomitant
drug use, and non-drug treatments; (4) physical examina-
tions including height, weight, pulse rate and blood pres-
sure, electrocardiogram (ECG), and routine laboratory
examinations; (5) safety; and (6) efficacy measures.
Safety analysis included recording the presence/absence,
date of onset, and seriousness of adverse drugs reactions
(ADRs; disorders, symptoms, and abnormal laboratory
findings for which a causal relationship to fluvoxamine
cannot be ruled out), the treatments received for ADRs,
final outcome of ADRs, causal relationship between ADRs
and fluvoxamine treatment and alternative etiology. Seri-
ousness of ADRs was defined in accordance with the ICH
E2A guideline (http://www.ich.org/fileadmin/Public_Web_
Site/ICH_Products/Guidelines/Efficacy/E2A/Step4/E2A_
Guideline.pdf). If an ADR did not meet any of the criteria
in the guideline, the ADR was defined as a non-serious
ADR. In addition, the occurrence of ADRs related to sui-
cide attempt, gastrointestinal hemorrhage, and cardiovas-
cular ADRs (including abnormal ECG findings) was
monitored.
Overall improvement in SAD during fluvoxamine
treatment compared with baseline was assessed at weeks
12, 24, 36, 48, and 53 or at the discontinuation/conclusion
of treatment using the 7-rank Clinical Global Impression
for Improvement (CGI-I) scale: 1, very much improved; 2,
much improved; 3, minimally improved; 4, no change; 5,
minimally worse; 6, much worse; and 7, very much worse.
Response was defined as the proportion of patients rated
‘‘very much improved’’ or ‘‘much improved’’ by investi-
gators according to the overall improvement rating using
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the 7-rank CGI-I scale. Patients comorbid with depression/
depressive state or OCD were also assessed for overall
improvement in depression/depressive state or OCD at
week 53 or at the discontinuation/conclusion of fluvox-
amine treatment.
Severity of SAD symptoms and responses to treatment
were also assessed using the LSAS-J. LSAS-J scores were
recorded at baseline and weeks 12, 24, 36, 48, and 53 of
treatment, or at the time of discontinuation/conclusion of
fluvoxamine treatment. The Japanese version of the Shee-
han Disability Scale (SDISS) was also used to assess the
severity of psychosocial disorder (work/school, social life,
home life, or family responsibilities), which was used as a
measure of quality of life (QOL).
Statistical Analysis
Logistic regression analysis was used to assess the effects
of factors that may affect occurrence of ADRs and
improvement in SAD. The one-sample Wilcoxon signed
rank test and t test were used to compare total LSAS-J and
SDISS scores before and after treatment, and the chi-square
test was used for other analyses. A two-sided p value less
than 0.05 was considered significant.
Ethics Approval
The survey at each medical institution was conducted
according to the clinical research agreement between the
institution and Abbott Japan or Meiji Seika Pharma, and
the protocol, including all ethical items, was approved by
the institutional review board at each institution.
Results
CRFs for 1,974 patients were retrieved from 407 medical
institutions nationwide. Of these, 184 patients were
excluded from the analysis (the majority because of lack of
follow-up visits), leaving 1,790 patients in the safety ana-
lysis set (Fig. 1). Among the 1,790 patients eligible for
safety analysis, 286 patients were excluded from the effi-
cacy analysis set, with the remaining 1,504 patients ana-
lyzed for efficacy. A total of 749 patients received
fluvoxamine for the full 53-week observation period.
The baseline characteristics of the 1,790 patients inclu-
ded in the safety analysis set are shown in Table 1. Patients
had a mean age of 32.6 ± 11.3 years and 49.4 % of
patients were male. Comorbid disorders were present in
41.1 % of patients, with approximately half of these
patients comorbid with depression or depressive state.
In the majority of patients (75.4 %), fluvoxamine was
given in combination with an antianxiety drug such as
alprazolam, etizolam, and ethyl loflazepate. The mean
daily dose of fluvoxamine reported for each patient was
25–50 mg in 24.0 %, 75–100 mg in 23.0 %, and more than
100 mg in 33.7 % (Table 1).
In addition, over the observation period, the mean daily
dose of fluvoxamine was higher among patients with higher
baseline total LSAS-J scores (Supplementary Tables 1, 2).
Furthermore, the prevalence of comorbidity with depres-
sion/depressive state was higher among patients with
higher total LSAS-J scores at baseline (Supplementary
Table 3).
Safety
Over the observation period, 526 ADRs were reported in
326 patients. The most common ADRs included nervous
system or gastrointestinal disorder-related events such as
nausea (112 events), somnolence (85 events), constipation
(22 events), and diarrhea (20 events) (Table 2). Non-
serious ADRs accounted for 95.1 % of all the ADRs
reported; 26 serious ADRs were reported in 15 patients,
including six events of suicide attempt, three events of
suicide ideation, and two events each of malaise, sedation,
and somnolence.
Of the 526 ADRs reported during the observation per-
iod, 33.5 % (176/526 events) developed in the first week of
treatment and 55.7 % (293/526 events) developed in the
first 4 weeks of treatment (Supplementary Table 4). The
incidence of ADRs reported in the second half of the
observation period (week 25–53) was lower than that
during the first 24 weeks of treatment, and there was no
tendency toward an increase in the incidence of ADRs in
patients receiving long-term treatment with fluvoxamine.
ADRs were totally improved in 86.5 % of cases.
Factors possibly affecting the occurrence of ADRs with
fluvoxamine treatment include gender, comorbid disorders
or complications, hepatic diseases, and allergies. Over the
observation period, the incidence of ADRs was 16.2 % in
men and 20.2 % in women, and was higher in patients with
comorbid disorders or complications, hepatic diseases, or
history of allergy than those without the corresponding
factor (Supplementary Table 5). The analysis of the rela-
tionship between dose and incidence of ADRs based on the
total dose at the onset of these ADRs revealed a higher
incidence among patients with a smaller total dose
(Table 3), which indicates that patients experienced ADRs
mainly in the first weeks of fluvoxamine treatment at lower
doses.
Four ADRs were considered important items of inves-
tigation in this survey (ADRs related to suicide attempt,
gastrointestinal hemorrhage, cardiovascular ADRs, and
sexual function disorders). No patients experienced gas-
trointestinal hemorrhage during the observation period.
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Over the observation period, 12 ADRs related to suicide
attempt were reported in nine patients and consisted of six
suicide attempts, three events of suicidal ideation, two
events of intentional overdose, and one event of self-inju-
rious behavior. The 12 ADRs related to suicide attempt
consisted of two non-serious events of intentional overdose
and ten serious ADRs. Patients recovered from five events,
the remaining events were considered ‘‘improved’’ (one
event), ‘‘not recovered’’ (three events), and ‘‘unknown’’
(one event). Patient characteristics analysis showed that
age and comorbidity with depression/depressive state were
significantly associated with the occurrence of attempted
suicide. Among the nine patients in this study who
attempted suicide, five patients were 24 years of age or
younger, and three of them had depression/depressive state
(Supplementary Table 6).
An ECG evaluation was requested as an important but
non-mandatory item in CRFs and conducted in 281
patients. However, only 62 of these patients underwent
ECG both before and after fluvoxamine treatment and the
other 219 patients lacked any of data to be evaluated.
Completed data of the 62 patients showed no prolonged QT
interval which had been reported as a rare finding of
clinically problematic abnormality of fluvoxamine before
initiation of this survey [15, 16]. One patient was reported
to show ‘‘ventricular extrasystoles’’ at 1 month after the
start of administration but no adverse event affecting the
cardiovascular system was reported for this patient. Inde-
pendently from this ECG evaluation, cardiovascular ADRs
were reported in eight patients and included six events of
palpitation and one event each of sinus tachycardia and
tachycardia. The eight cardiovascular ADRs were not
Fig. 1 Flow chart of patients through the study. aSome patients had more than one reason for exclusion; bpsychiatric illnesses included
schizophrenia (n = 6), borderline personality disorder (n = 1), and obsessive-compulsive disorder (n = 1)
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serious, and the outcome was ‘‘recovered’’ or ‘‘improved’’.
An analysis of factors influencing the rate of cardiovascular
ADRs revealed that a lower total dose of fluvoxamine at
the onset of cardiovascular ADRs was significantly asso-
ciated with a higher incidence of cardiovascular ADRs
(Supplementary Table 7). No ECG data were available for
these eight patients.
Eight events of sexual function disorders were reported
in six patients, including delayed ejaculation, ejaculation
disorder, sexual dysfunction, and erectile dysfunction with
two of each event reported. All eight ADRs were not
considered serious. Two events were not considered
recovered (delayed ejaculation and sexual dysfunction)
while the remaining events were all considered ‘‘recov-
ered’’ or ‘‘improved’’. Patient characteristic analysis
showed that the presence of past illness and lower baseline
total LSAS-J scores were significantly associated with a




A clinical response rate was reported in 62.6 % of the
1,504 patients analyzed for efficacy and 78.4 % of the 749
patients who received fluvoxamine treatment for the entire
53-week observation period. In the patients who received
53 weeks of fluvoxamine treatment, the response rate to
fluvoxamine treatment was higher in patients who did not
have any complications or comorbid disorders and also in
patients without comorbidity with depression/depressive
state. In contrast, concomitant drug treatment had no sig-
nificant effect on the response rate (Supplementary
Table 9). The response rate was also higher in patients with
mild SAD (indicated by lower total LSAS-J and SDISS
scores at baseline; Table 4). Similar results were obtained
in the 1,504 patients eligible for efficacy analysis.
Change Over Time in Overall Improvement Rating
The response rates at weeks 12, 24, 36, 48, and 53 in the
749 patients who received fluvoxamine for the full
53 weeks of observation were 39.6, 57.3, 68.5, 74.3, and
78.4 %, respectively, showing an increase in response over
time (Supplementary Fig. 1). Similarly, the response rates
at weeks 12, 24, 36, 48, and 53 in the 1,504 patients ana-
lyzed for efficacy were 39.7, 56.0, 67.6, 74.1, and 78.4 %,
respectively, indicating an increase in response rate in
association with a longer duration of treatment.
Change Over Time in the LSAS-J Score
Over the 53-week fluvoxamine treatment period, total
LSAS-J scores decreased rapidly during the first
12 weeks, and continued to significantly decrease over the
remainder of the treatment period (Fig. 2; all p \ 0.0001,
n = 184). Similarly, the fear/anxiety and avoidance
LSAS-J sub-scale scores substantially decreased over the
first 12 weeks of fluvoxamine treatment and continued to
decrease over the remainder of the trial (p \ 0.0001 at all
time points).
Table 1 Baseline characteristics of the safety analysis set
Characteristic Safety analysis set
[N = 1,790; n (%)]
Age, years




Comorbid disordersa 736 (41.1)
Depression or depressive state 377 (21.1)
Obsessive compulsive disorder 58 (3.2)
Hepatic diseases 47 (2.6)
Renal diseases 7 (0.4)
Other 489 (27.3)
Concomitant therapies 1,349 (75.4)
Alprazolam 361 (20.2)
Etizolam 237 (13.2)
Ethyl loflazepate 221 (12.3)
Mosapride citrate hydrate 220 (12.3)
Sulpiride 211 (11.8)














Not assessed 147 (8.2)
All values are n (%) unless otherwise stated
LSAS-J Liebowitz Social Anxiety Scale-Japanese version, SD stan-
dard deviation
a Data missing for 11 (0.6 %) patients
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Change Over Time in SDISS
Among 749 patients who continued fluvoxamine for
53 weeks, 167 patients were evaluated using the SDISS. At
baseline, the proportion of patients rated as ‘‘unimpaired’’
or ‘‘slightly impaired’’ was 15.0, 21.6, and 67.7 % in the
‘‘work/school’’, ‘‘social life’’, and ‘‘home life or family
responsibilities’’ domains, respectively. With fluvoxamine
treatment the proportion of patients rated as unimpaired or
slightly impaired increased to 38.3, 46.1, and 77.8 % of
patients at week 12, and to 80.2, 83.2, and 91.0 % at week
53, respectively, indicating a continuous improvement in
QOL during treatment with fluvoxamine (Fig. 3; all
p \ 0.0001).
Fluvoxamine Efficacy in Patients Comorbid
with Depression or Depressive State
In the 163 patients comorbid with depression at baseline who
completed 53 weeks of fluvoxamine treatment, significantly
more patients whose depression improved over the obser-
vation period had a response in SAD with fluvoxamine
treatment (86.4 vs. 35.8 % of patients in the depression
improvement and non-improvement groups, respectively;
p \ 0.0001). Furthermore, patients whose depression
improved over the observation period had a significantly
greater reduction in total LSAS-J score from baseline to
week 53 than those whose depression did not improve
(Fig. 4). Similar results were observed with the change in
total SDISS scores over the observation period (Fig. 5).
Discussion
The efficacy of fluvoxamine for the treatment of SAD has
previously been demonstrated in both non-Japanese [17,
18] and Japanese [6] patients in studies of 10–12 weeks
duration. Furthermore, the long-term treatment (24 weeks)
of patients with SAD with a controlled-release formula-
tion of fluvoxamine (fluvoxamine CR) has also been
shown and confirmed the benefit of the pharmacotherapy
for SAD [19]. The current report describes for the first
time the results of a survey on the longer-term (53 weeks)
safety and efficacy of fluvoxamine in a sufficiently large
number of Japanese patients with SAD in the clinical
setting. Indeed, a total of 1,974 patients from 407
nationwide medical institutions participated in the survey
to cover a wide range of age (11–83 years old) and
comorbidity with depression/depressive state. SAD often
develops in patients in their mid-teens and early 20s, and
many patients have SAD for several years before visiting
the clinic [20]. The patient population in the present
survey, in which patients in their 20s were the largest age
group, and those in their 20s and 30s accounted for about
65 % of participants, well represents patients with SAD in
Japan. Therefore, the current report well represents out-
comes of SAD treatment with fluvoxamine in the ‘real
world’.
Of the 1,790 patients analyzed for safety, 18.2 %
experience an ADR. Nausea, somnolence, and constipation
were most commonly observed, which was consistent with
previous studies [1–5, 21]. Although 26 serious ADRs
Table 2 Nervous system or gastrointestinal event-related adverse drug reactions reported in patients receiving fluvoxamine
Any ADR 326 (18.2) Any gastrointestinal disorder 173 (9.66)
Any nervous system disorder 112 (6.26) Abdominal discomfort 11 (0.61)
Akathisia 3 (0.17) Abdominal distension 1 (0.06)
Altered state of consciousness 1 (0.06) Abdominal pain 5 (0.28)
Convulsion 1 (0.06) Abdominal pain upper 9 (0.50)
Disturbance in attention 2 (0.11) Constipation 22 (1.23)
Dizziness 14 (0.78) Diarrhoea 20 (1.12)
Dizziness postural 2 (0.11) Dyspepsia 1 (0.06)
Drug withdrawal headache 1 (0.06) Enteritis 1 (0.06)
Head discomfort 1 (0.06) Flatulence 1 (0.06)
Headache 13 (0.73) Gastritis 6 (0.34)
Hypoesthesia 4 (0.22) Gastroduodenal ulcer 1 (0.06)
Sedation 6 (0.34) Nausea 112 (6.26)
Sensory loss 1 (0.06) Oral discomfort 2 (0.11)
Somnolence 85 (4.75) Reflux esophagitis 1 (0.06)
Tremor 1 (0.06) Stomach discomfort 3 (0.17)
Poor quality sleep 1 (0.06) Vomiting 2 (0.11)
Intestinal functional disorder 1 (0.06)
Safety analysis set [N = 1,790; n (%)]. Some patients had more than one ADR
ADR adverse drug reaction
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occurred in 15 patients, 95.1 % of the ADRs reported in the
survey were not serious. Of the 526 ADRs reported during
the observation period, the majority of the events devel-
oped in the first 4 weeks of fluvoxamine treatment. There
was no tendency for the incidence of ADRs to increase
over time during treatment. An analysis of the incidence of
ADRs by maximum daily dose of fluvoxamine did not
reveal a dose-related increase in the incidence of ADRs. In
fact, the incidence of ADRs was higher during the first few
weeks of treatment, during which patients received flu-
voxamine at lower doses. This suggests that physicians
should carefully observe their patients for occurrence of
ADRs during the first weeks of treatment.
In this observational study, four ADRs were considered
important items of investigation in this survey (ADRs
related to suicide attempt, gastrointestinal hemorrhage,
cardiovascular ADRs, and sexual function disorders).
ADRs related to suicide attempt were considered an
important item, as it has been shown previously that some
antidepressants increase the risk of suicide ideation and
behavior in children, adolescents, and young adults (aged
18–24) during initial treatment [22]. It has also been
reported that the combination of SSRIs and non-steroidal
anti-inflammatory drugs increases the risk of upper gas-
trointestinal hemorrhage [23–25]. Although the effects of
fluvoxamine on the cardiovascular system are reported to
be less severe than those of tricyclic antidepressants [26],
and the incidence of cardiovascular ADRs associated with
fluvoxamine was significantly lower as compared with
imipramine [21], there have been spontaneous reports of
cardiovascular ADRs such as prolonged QT interval in
association with fluvoxamine treatment in Japan [27]. As
such we carefully monitored these ADRs during this
study. In addition to the above important items of inves-
tigation, occurrence of sexual dysfunction was investi-
gated, as a high rate of this ADR has been reported in a
Western clinical study [28] but was low in a study in
Japan [21].
Age and the presence of depression/depressive state
were identified as significant factors potentially affecting
the rate of suicide attempt in this study. As such close
observation of the condition and change of pathophysiol-
ogy during the early phase of treatment with fluvoxamine,
or after changing its dose, is important in patients under
24 years of age with SAD comorbid with depression/
depressive state.
All cardiovascular ADRs observed in the survey were
not serious and no patient showed QT prolongation or other
ECG findings. Since the total dose of fluvoxamine was
analyzed by the onset of the ADRs and many of them
developed in the first 4 weeks of treatment, the incidence
of ADRs was significantly higher in patients with a smaller
total dose. Therefore, physicians should carefully observe
Table 3 Effect of fluvoxamine dose and baseline LSAS-J scores on
the occurrence of adverse drug reactions (ADRs)
Na ADRs, n (%) Logistic regression analysis
OR 95 % CI p value
Total dose of fluvoxamine, gb
B2 328 207 (63.1) 0.631 0.594, 0.670 \0.0001
2–4 126 26 (20.6)
4–8 160 22 (13.8)
8–12 118 19 (16.1)
12–16 95 11 (11.6)
16–20 157 10 (6.4)
20–24 75 5 (6.7)
24–28 81 11 (13.6)
28–32 79 3 (3.8)
32–36 68 2 (2.9)
36–40 91 3 (3.3)
[40 408 4 (1.0)
Unknown 4 3 (75.0)
Maximum daily dose of fluvoxamine, mgb
B25 65 18 (27.7) 0.714 0.663, 0.768 \0.0001
25–50 423 142 (33.6)
50–75 177 22 (12.4)
75–100 447 79 (17.7)
100–125 14 2 (14.3)
125–150 505 46 (9.1)
[150 mg 155 14 (9.0)
Final daily dose of fluvoxamine, mgb
B25 118 22 (18.6) 0.775 0.721, 0.833 \0.0001
25–50 505 146 (28.9)
50–75 172 23 (13.4)
75–100 457 82 (17.9)
100–125 11 3 (27.3)
125–150 407 3 (8.6)
[150 116 12 (10.3)
Baseline LSAS-J total score
B29 97 16 (16.5) 1.007 0.956, 1.060 0.7961
30–39 81 12 (14.8)
40–49 130 25 (19.2)
50–59 173 35 (20.2)
60–69 191 35 (18.3)
70–79 224 40 (17.9)
80–89 211 43 (20.4)
90–99 213 37 (17.4)
C100 323 59 (18.3)
B59 481 88 (18.3) 1.008 0.766, 1.327 0.9540
C60 1,162 214 (18.4)
ADR adverse drug reaction, CI confidence interval, LSAS-J Liebowitz
Social Anxiety Scale-Japanese version, N number of patients, OR odds
ratio
a Patients with no relevant information were excluded from analysis
b Total dose of fluvoxamine for patients with ADRs was calculated as
total dose by the onset of the first ADR
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their patients for cardiovascular ADRs to fluvoxamine
which tend to develop more frequently in the early phase of
treatment, as in the case of other types of ADRs.
The response to fluvoxamine observed in this survey
was similar to that shown in another 52-week open-label
long-term clinical study of SAD in Japan [6]. For overall
improvement rating, the response rate in 749 patients who
continued fluvoxamine treatment for 53 weeks was
39.6 % at week 12, and 78.4 % at week 53, showing an
increase in response rate over time. The total LSAS-J
score also significantly decreased from 78.4 ± 26.4 points
at baseline to 61.5 ± 26.6 points at week 12, and
41.6 ± 27.8 points at week 53 (p \ 0.0001). Both overall
improvement rating and total LSAS-J score significantly
improved in the first 12 weeks of fluvoxamine treatment
and continued to improve by week 53. Therefore, long-
term efficacy of fluvoxamine in the treatment of SAD was
confirmed. It is notable that there was no difference
between patient groups with or without concomitant
drugs, suggesting efficacy of long-term monotherapy with
fluvoxamine.
SSRIs are commonly used as first-line pharmacotherapy
for SAD on the basis of their clinical merits compared to
placebo, and response rates in controlled studies were
reported to range from 43 to 70 % in active arms (7–32 %
in placebo) [17, 18, 29–33]. In agreement with such pre-
vious reports, overall response rate to fluvoxamine in this
observation study was 62.6 % and the other 37.4 % of
patients needed second-line treatment. No standardized
guideline indicating treatment options for non-responder
SAD patients to SSRIs is available, so far. Although some
reports suggest positive effects of switching to a different
SSRI or other class of pharmacotherapy, including sero-
tonin–noradrenaline reuptake inhibitors, antiepileptic
drugs, benzodiazepines, and antipsychotics, scientific evi-
dence is limited to support their clinical merits [34, 35].
The value of cognitive behavioral therapy (CBT) for SSRI
non-responder patients of other anxiety disorders such as
obsessive-compulsive disorder or panic disorder was sys-
tematically reviewed [36]. However, clinical data to sup-
port the merits of CBT for SSRI non-responder SAD
patients are not abundant enough to be discussed and we
need to wait for upcoming results of controlled studies [37,
38]. In conclusion, fluvoxamine should be used for SAD
treatment but with an understanding of its response rate
described here, accompanied by careful monitoring of
serious ADRs, such as suicide attempt in cases of young
patients.
The response rate of SAD in the current survey was
significantly affected by the presence of comorbidity of
depression or depressive state. Indeed, SAD is often
associated with depression: an epidemiological study
revealed that 34 % of patients with SAD have comorbidity
Table 4 Relationship of responder rate to fluvoxamine dose, baseline
LSAS-J, and SDISS scores
Na Response n (%) Logistic regression analysis
OR 95 % CI p value
Total dose of fluvoxamine, gb
B2 0 0 (0) 0.944 0.873, 1.020 0.1440
2–4 0 0 (0)
4–8 0 0 (0)
8–12 12 10 (83.3)
12–16 6 5 (83.3)
16–20 81 66 (81.5)
20–24 43 37 (86.0)
24–28 42 35 (83.3)
28–32 42 30 (71.4)
32–36 44 33 (75.0)
36–40 81 67 (82.7)
[40 398 304 (76.4)
Maximum daily dose of fluvoxamine, mgb
B25 10 8 (80.0) 0.894 0.805, 0.992 0.0355
25–50 110 93 (84.5)
50–75 73 57 (78.1)
75–100 174 141 (81.0)
100–125 6 5 (73.3)
125–150 283 214 (75.6)
[150 mg 93 69 (74.2)
Final daily dose of fluvoxamine, mgb
B25 33 29 (87.9) 0.876 0.795, 0.966 0.0080
25–50 151 125 (82.8)
50–75 74 57 (77.0)
75–100 190 154 (81.1)
100–125 6 5 (83.3)
125–150 224 166 (74.1)
[150 71 51 (71.8)
Baseline LSAS-J total score
B29 39 36 (92.3) 0.893 0.826, 0.966 0.0048
30–39 29 20 (69.0)
40–49 52 46 (88.5)
50–59 71 60 (84.5)
60–69 83 68 (81.9)
70–79 100 75 (75.0)
80–89 92 68 (73.9)
90–99 94 74 (78.7)
C100 147 106 (72.1)
B59 191 162 (84.8) 0.560 0.359, 0.873 0.0104
C60 516 391 (75.8)
Baseline SDISS total score
B9 168 139 (82.7) 0.665 0.502, 0.882 0.0046
10–19 362 294 (81.2)
C20 134 92 (68.7)
CI confidence interval, LSAS-J Liebowitz Social Anxiety Scale-Japanese
version, N number of patients, OR odds ratio, SDISS Sheehan Disability
Scale
a Patients with no relevant information were excluded from analysis
b Total dose of fluvoxamine for patients with ADRs was calculated as
total dose by the onset of the first ADR
14 S. Asakura et al.
of depression as well [39]. The presence of depression/
depressive state is believed to be an important predictor of
poor response to treatment in patients with SAD [40, 41].
The response rate was high in both groups of patients but
the response rate was about 10 % lower in patients with
comorbidity of depression/depressive state: among
patients who continued fluvoxamine for 53 weeks, the
response rate was 80.7 % in patients without comorbidity
of depression or depressive state and 69.9 % in patients
with it. In order to clarify the treatment effect of fluvox-
amine on SAD patients with depression, 163 out of 749
patients who had depression/depressive state and contin-
ued fluvoxamine treatment for 53 weeks were stratified
into those whose depression/depressive state was
improved over the study period versus those whose
depression did not improve, and analyzed for the
improvement rate of SAD. The response rate was 35.8 %
in patients whose depression/depressed state did not
improve and 86.4 % in patients with its improvement. The
analysis of change over time of total LSAS-J score
revealed that the score did not decrease at week 36 and
thereafter in patients without improvement of depression/
Fig. 2 Change from baseline
over the 53-week study period
in total, fear/anxiety sub-scale,
and avoidance sub-scale scores
on the Liebowitz Social Anxiety
Scale-Japanese version (LSAS-
J) with fluvoxamine treatment.
*p \ 0.0001 vs. baseline
Fig. 3 Change from baseline
over the 53-week study period
in total, work/study domain,
social life, and home life or
family responsibilities domain
scores on the Sheehan Disability
Scale (SDISS) with fluvoxamine
treatment. *p \ 0.0001 vs.
baseline
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depressive state, whereas it continued to decrease signifi-
cantly at all points from week 12 through to 53 in patients
with the improvement, resulting in significantly higher
treatment response to fluvoxamine. The total SDISS score,
a measure of QOL, also continued to decrease significantly
from week 12 through to week 53 in patients with
improvement in depression/depressive state, demonstrating
their good response to fluvoxamine.
It is generally accepted that depression–anxiety comor-
bidity results in poor treatment outcomes and requires a
more careful treatment strategy [42]. The results of the
current survey indicate that the response rate of SAD
patients with depression/depressive state to fluvoxamine
was significantly lower and improvement in their depres-
sion/depressive state by fluvoxamine in SAD patients could
predict better improvement in symptoms of SAD in a real-
Fig. 4 Change from baseline
over the 53-week study period
in total Liebowitz Social
Anxiety Scale-Japanese version
(LSAS-J) score in patients who
did or did not report an
improvement in depression
(n = 155). *p \ 0.05 vs.
baseline; **p \ 0.01 vs.
baseline; ***p \ 0.001 vs.
baseline; p \ 0.05 vs. patients
whose depression did not
improve; p \ 0.01 vs. non-
improved patients;
p \ 0.0001 vs. non-improved
patients
Fig. 5 Change from baseline
over the 53-week study period
in total Sheehan Disability Scale
(SDISS) score in patients who
did or did not report an
improvement in depression
(n = 145). *p \ 0.05 vs.
baseline; **p \ 0.01 vs.
baseline; ***p \ 0.001 vs.
baseline; p \ 0.05 vs. patients
whose depression did not
improve; p \ 0.01 vs. non-
improved patients;
p \ 0.0001 vs. non-improved
patients
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world setting. It has also been reported that improvement in
depression/depressive state is followed by improvement in
SAD [40]. Therefore, the survey indicates again the
importance of the treatment of depression/depressive state
in addition to that of SAD in patients where these condi-
tions coexist. On the other hand, a previous report showed
no significant difference of treatment response to another
SSRI, escitalopram, between SAD patients with and
without depressive state during up to 24 weeks of treat-
ment [43]. The longer observation period (53 weeks) of our
survey might be better to find the difference and/or
exclusion criteria of such controlled studies that might
cause a kind of mask compared to the real-world survey.
Alternatively, pharmacological differences between flu-
voxamine and escitalopram could bring different outcomes
on this point. Indeed, fluvoxamine has a unique property as
a sigma-1 agonist that seems to contribute its clinical
effects in part [44]. Continued effects of fluvoxamine on
responders with depression/depressive state might come
from network remodeling through sigma-1 agonism [45],
although it requires more studies to be proved.
Finally, it should be noticed that there are limitations in
this study caused by its design. All of the observations in
this study do not have independent controls because the
study was performed under clinical settings in the ‘‘real
world’’. Concerning comorbidity with depression/depres-
sive state, no detailed data were obtained in this survey,
because the protocol did not contain full assessment of
depression by structured interview. Therefore, we cannot
exclude possible cases of major depression, dysthymic
disorder, or bipolar depression in this study.
Conclusions
This study confirms the long-term efficacy and safety of
fluvoxamine for the treatment of SAD in Japanese patients
in a clinical setting. Most ADRs were observed in the early
treatment phase, and improvement of coexisting depres-
sion/depressive state was confirmed as an important factor
influencing the treatment response of SAD itself. The
findings in this study are an important addition to the lit-
erature on SAD, showing how to treat the disorder appro-
priately with fluvoxamine.
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